A control study of aripiprazole and tiapride treatment for tic disorders in children

LIU Yan-Yan; CHEN Yan-Hui; CHEN Hui; LIU Zhi-Sheng

PDF(975 KB)

Chinese Journal of Contemporary Pediatrics ›› 2010, Vol. 12 ›› Issue (06) : 421-424.

CLINICAL RESEARCH

A control study of aripiprazole and tiapride treatment for tic disorders in children

LIU Yan-Yan, CHEN Yan-Hui, CHEN Hui, LIU Zhi-Sheng

Author information +

History +

Abstract

OBJECTIVE: To evaluate the efficacy and safety of aripiprazole in the treatment of tic disorder when tiapride is used as a control. METHODS: Sixty-five children aged 6-14 years old with tic disorders were randomly assigned to two groups: aripiprazole (2.5-10 mg/d) and tiapride treatment (25- 400 mg/d). After 12 weeks treatment, the clinical efficacy was assessed by the Yale Global Tie Severity Scale (YGTSS) score and the adverse reactions were observed. RESULTS: The YGTSS score in both groups decreased from the second week of treatment. Compared with the tiapride treatment group, the aripirazole treatment group showed a more decreased YGTSS score ［(29±13)% vs (16±14)%; P<0.01］ by the second week of treatment. The overall effective rate in the aripiprazole and tiapride treatment groups was 91% and 84%, respectively (P>0.05) 12 weeks after treatment. There were no significant differences in the incidence of adverse reactions between the aripiprazole and tiapride treatment groups and no severe adverse events were found in either group. CONCLUSIONS: Low dose aripiprazole is safe and effective for treatment of tic disorders in children, suggesting that it represents a new valid option for the treatment of tic disorder.［Chin J Contemp Pediatr, 2010, 12 (6):421-424］

Key words

Tic disorders / Aripiprazole / Tiapride / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LIU Yan-Yan, CHEN Yan-Hui, CHEN Hui, LIU Zhi-Sheng. A control study of aripiprazole and tiapride treatment for tic disorders in children[J]. Chinese Journal of Contemporary Pediatrics. 2010, 12(06): 421-424

References

［1］陈会，钟佑泉，何志旭．儿童抽动障碍的免疫因素［J］．重庆医学, 2007, 36（20）：2107-2109．
［2］杜亚松，李华芳，钟佑泉，焦富勇，于得澧，王惠梅，等．可乐定透皮贴剂治疗抽动障碍的随机、双盲、安慰剂对照、多中心临床试验［J］．上海精神医学, 2006, 18（4）：193-198．
［3］吴仁容，李乐华．新型抗精神病药：阿立哌唑［J］．国外医学精神病学分册, 2004, 31(3)：177-179.
［4］Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis［J］. Prog Brain Res, 2008, 172:199-212.
［5］Seo WS, Sung HM, Sea HS, Bai DS. Aripiprazole treatment of children and dolescents with Tourette disorder or chronic Tic disorder［J］. J Child Adolesc Psychopharmacol, 2008, 18(2):197-205.
［6］Davies L, Stern JS, Agrawal N, Robertson MM. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole［J］. Hum Psychopharmacol, 2006, 21(7):447-453.
［7］Miranda CM, Castiglioni TC. Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients［J］. Rev Med Chil, 2007,135(6):773-776.
［8］American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Text Revision) ［M］. Washington, DC:American Psychiatric Association, 2000:1-943.
［9］Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity［J］. J Am Acad Child Adolesc Psychiatry, 1989, 28(4): 566-573.
［10］Kane JM. Optimizing pharmacotherapy to maximize outcome in schizophrenia［J］. J Clin Psychiatry, 2005, 66(1):122133.
［11］Haupt DW. Differential metabolic effects of antipsychotic treatments［J］. Eur Europsychopharmacol, 2006, 16(s3):149-155.
［12］Ben Djebara M, Worbe Y, Schupbach M, Hartmann A. Aripiprazole: A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome［J］.Movement Disorders, 2008, 23(3):438-440.
［13］Murphy TK, Bengtson MA, Soto O, Edge PJ, Sajid MW, Shapira N, et al. Case series on the use of aripiprazole for Tourette syndrome［J］. Int J Neuropsychopharmacol, 2005, 8(3):489-490.
［14］张彬，寇金爱．不同剂量阿立哌唑治疗精神分裂症的临床研究［J］. 中华临床医学研究杂志，2008，14(3)：310-311.